0812 GMT - Smith & Nephew's results topped expectations, with reassuring strength in particular at its U.S. orthopedics business, which will be welcomed by investors, RBC Capital Markets analysts say in a note. The U.K. medical-technology company's 4Q orthopedics underlying growth of 6% was ahead of RBC's expectations of 4.9%, driven by strength in its hips and knees business in the U.S., the analysts say. The company posted a 2025 outlook in line with consensus and expects China headwinds to clear through 1Q, in line with previous commentary, they say. Shares are up 9.7% at 1,144.50 pence. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 25, 2025 03:12 ET (08:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.